Lynparza
Merck Talks Up Pipeline Diversification as Demand for Keytruda, Facing Patent Expirations, Grows
Premium
The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.
NICE Recommends Lynparza for BRCA1/2-Mutant Breast Cancer
The institute originally began reviewing Lynparza in this setting in 2018 but ended its review due to lack of evidence.
Foundation Medicine Nets FDA Approval for Tissue, Liquid NGS CDx for Lynparza Combo
The FDA approved FoundationOne CDx and FoundationOne Liquid for identifying BRCA1/2-mutated mCRPC patients eligible for Lynparza, Zytiga, and a steroid.
Keytruda Sales Climb 16 Percent in Q2 as Merck Pursues New Oncology Candidates
The drugmaker updated investors on its three-pronged strategy to diversify its pipeline and not overly rely on its top-selling blockbuster checkpoint inhibitor.
Tango Therapeutics Scraps USP1 Inhibitor Trial Due to Toxicities
In a Phase I/II trial in patients with BRCA1/2-mutated and other HRD-positive solid tumors, TNG348 caused serious liver function abnormalities.
Mar 21, 2024
Jan 30, 2024